ResearchGeneral gynecologyDepot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection
Section snippets
Study subjects and data collection
The University of Washington Human Subjects Division approved all protocols and consent forms. As described previously, women presenting from December 1997 through August 2002 for routine gynecologic care at 3 Planned Parenthood clinics who met the following criteria were eligible for cytologic and HPV screening with the study: were 18-50 years old; had no history of treatment for cervical neoplasia or hysterectomy; were not planning to continue a current pregnancy; and did not report being
Hormonal contraception and CIN
Of the 458 subjects in the analysis who were oncogenic HPV–positive at colposcopy-biopsy, 377 (83%) were also oncogenic HPV–positive at screening, and of these, 345 (92%) were positive for the same type. At colposcopy-biopsy, HPV16 was detected in specimens from 43 (28%) of the women with negative histology, 27 (20%) of the women with CIN1, and 90 (52%) of the women with CIN2-3 or greater. CIN cases were more likely than controls to have 2 or more oncogenic HPV types detected at
Comment
Among women with oncogenic HPV, those with CIN were slightly less likely than women with negative histology to report ever use of DMPA in the previous year (borderline statistical significance for CIN2-3 or greater). COC use was not associated with CIN2-3 or greater or with CIN1. Recent use of DMPA for 1 year or longer was positively associated with detection of oncogenic HPV. This relationship did not appear to be caused by HPV persistence as measured by type-specific repeat oncogenic HPV
Acknowledgment
We thank Planned Parenthood, Kim Tomlinson, Akhila Balasubramanian, and Connie Nelson for their work on the Evaluation of Screening Methods for Cervical Cancer Study and Dr Thomas Lumley for his participation on Dr Harris's dissertation committee.
References (40)
- et al.
Cervical cancer and use of hormonal contraceptives: a systematic review
Lancet
(2003) - et al.
Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States
Am J Obstet Gynecol
(2008) - et al.
Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study
Lancet
(2002) - et al.
Immunity to oncogenic human papillomaviruses
Adv Cancer Res
(2001) - et al.
Oncogenic transformation by human papillomavirus type 16 deoxyribonucleic acid in the presence of progesterone or progestins from oral contraceptives
Am J Obstet Gynecol
(1990) - et al.
Colposcopic appearance of cervical intraepithelial neoplasia is age dependent
Am J Obstet Gynecol
(1998) - et al.
Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium
Obstet Gynecol
(2000) - et al.
The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy
Contraception
(1999) - et al.
Prevalence of visible disruption of cervical epithelium and cervical ectopy in African women using Depo-Provera
Contraception
(1999) - et al.
The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera
Contraception
(2000)
Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies
Lancet
Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort
Br J Cancer
Human papillomavirus infection and use of oral contraceptives
Br J Cancer
Incident infection with genital human papillomavirus: rates and risk factors in a cohort of college women
Am J Epidemiol
Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females
JAMA
Human papillomavirus infection at the United States-Mexico border: implications for cervical cancer prevention and control
Cancer Epidemiol Biomarkers Prev
Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology
Int J Cancer
Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys
Cancer Epidemiol Biomarkers Prev
Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa)
Cancer Causes Control
Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral
JAMA
Cited by (25)
Solid fuel use for heating and risks of breast and cervical cancer mortality in China
2020, Environmental ResearchCitation Excerpt :We assumed that some estrogen-like chemicals released from solid fuel combustion (especially PAHs), after entering into cervical tissue, might increase a woman's risk of developing cancer. On the contrary, progesterone was inhibitory for cervical carcinogenesis in vivo and associated with a reduced cancer risk among HPV-infected women (Baik et al., 2019; Harris et al., 2009; Yoo et al., 2013). For post-menopausal women with low level of sex hormones, potential preventive effect of progesterone may be attenuated.
Oral contraceptives use and risk of cervical cancer—A systematic review & meta-analysis
2020, European Journal of Obstetrics and Gynecology and Reproductive BiologyCitation Excerpt :Full details of the 19 studies included in the analysis were given in Web Table 1. A separate analysis was also done on 15 studies for OC pill use and risk of cervical cancer in HPV positive women [21,24,34,38–49] and included as a web source. A summary of included studies for study location along with the period of study, study design, sample size, study setting, and case ascertainment for each primary study were enlisted (Web Table 1).
Medroxyprogesterone Acetate Prevention of Cervical Cancer through Progesterone Receptor in a Human Papillomavirus Transgenic Mouse Model
2019, American Journal of PathologyPapanicolaou smear interpretation with progestin-only hormonal birth control methods
2016, Journal of Reproduction and ContraceptionCanadian Contraception Consensus (part 3 of 4): Chapter 8 - Progestin-only contraception
2016, Journal of Obstetrics and Gynaecology CanadaCitation Excerpt :Son utilisation ne semble pas engendrer une hausse des risques de cancer du sein197–200. Les résultats d’études récentes quant au cancer du col utérin sont rassurants et indiquent que ce cancer est associé au tabagisme plutôt qu’à l’utilisation d’AMPR201–204. Déclaration sommaire
Canadian Contraception Consensus (Part 3 of 4): Chapter 8 - Progestin-Only Contraception
2016, Journal of Obstetrics and Gynaecology CanadaCitation Excerpt :There does not appear to be an increased risk of breast cancer with DMPA use.197–200 Recent studies regarding cervical cancer are reassuring and show that cervical cancer is associated with smoking status rather than DMPA use.201–204 Summary Statement
Dr Harris is currently affiliated with the New York City Department of Health and Mental Hygiene, New York, NY.
This study was supported in part by Public Health Service Grant CA34493 from the National Cancer Institute.
Cite this article as: Harris TG, Miller L, Kulasingam SL, et al. Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection. Am J Obstet Gynecol 2009;200:489.e1-489.e8.